[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339088-105":59,"doc-detail-339088-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advanced-molecular-solutions-for-cancer-therapy-the-good-the-bad-and-the-ugly-of-the-biomarker-paradigm","Advanced Molecular Solutions for Cancer Therapy - The Good, the Bad, and the Ugly of the Biomarker Paradigm","","Editorial reviewing molecular strategies for cancer therapy framed by the biomarker paradigm. The text describes goals of identifying “actionable” molecules to selectively suppress cancer cell proliferation while minimizing effects on normal cells, and highlights contributors’ experimental work, genomic dataset reanalysis, and literature reviews. It contrasts promise and limitations of biomarker-driven diagnostics and therapies, discussing test kits, target plausibility, standardization of oncological procedures, and economic and reliability concerns across model systems and patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advanced-molecular-solutions-for-cancer-therapy-the-good-the-bad-and-the-ugly-of-the-biomarker-paradigm/339088/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advanced-molecular-solutions-for-cancer-therapy-the-good-the-bad-and-the-ugly-of-the-biomarker-paradigm/339088.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the molecular solutions discussed in the editorial?","Question",{"text":112,"@type":113},"To identify the most effective actionable molecules whose “smart” manipulation can selectively kill or slow cancer cell proliferation with few side effects on normal tissue cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which types of evidence sources do the contributing authors use?",{"text":117,"@type":113},"They contribute through accurate experiments, reanalyzing publicly accessible genomic datasets such as TCGA, and writing comprehensive literature reviews.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does the editorial question the biomarker paradigm?",{"text":121,"@type":113},"It calls for a candid discussion about how biomarkers are discovered, their real value for diagnosis and therapy, and how reliable their testing is in animal models and human cell cultures.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339088,1790884558,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Editorial  \nAdvanced Molecular Solutions for Cancer Therapy—The Good, the Bad, and the Ugly of the Biomarker Paradigm  \nDumitru Andrei Iacobas   \nCitation: Iacobas, D.A. Advanced Molecular Solutions for Cancer Therapy—The Good, the Bad, and the Ugly of the Biomarker Paradigm. Curr. Issues Mol. Biol. 2024, 46, 1694–1699 . [https://doi.org/10.3390/cimb46030109](https://doi.org/10.3390/cimb46030109)  \nReceived: 9 January 2024  \nAccepted: 17 February 2024  \nPublished: 22 February 2024  \nCopyright: © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nLaboratory of Personalized Genomics, Undergraduate Medical Academy, Prairie View A&M University, Prairie View, TX 77446, USA; [daiacobas@pvamu.edu](daiacobas@pvamu.edu); Tel.: +1-936-261-3086  \nIdentifying the most effective actionable molecules whose “smart” manipulation might selectively kill/slow down/stop the proliferation of cancer cells, with few side effects on the normal cells of the tissue, was for decades the single major objective of countless investigators. This Special Issue (SI), a continuation of the previous Current Issues in Molecular Biology SI “Molecules at Play in Cancer” [1], aimed to present the latest developments in the molecular solutions for cancer therapy, and the ways of personalizing the treatment to the individual characteristics of the patient. The authors have contributed their best efforts, either by performing accurate experiments, reanalyzing publicly accessible genomic datasets (including The Cancer Genome Atlas (TCGA) [2]), or writing comprehensive reviews of the literature. Among the interesting proposed solutions, of note are: the targeted delivery of chimeric antigen receptor into T cells via CRISPR [3], the metabolic silencing via methionine-based amino acid restriction [4], the inhibition of ERK5 [5], the activation of ADRA2A [6], and the aspirin treatment of breast cancer [7] .  \nMost articles dealing with molecular mechanisms that should be activated or inhibited to destroy the cancer cells either directly,(e.g., [5]), or by increasing the efficacy of immuno- [3,8], chemo- [6], and radiotherapy were aligned with the main stream “biomarker paradigm”(BMP) . For a long time, the vast majority of investigators and clinical oncologists have believed that the mutation and/or altered expression of certain genes, called“biomarkers”, are responsible for triggering cancerization. Moreover, it was hoped that restoring the normal status of such gene biomarkers would provide the natural anti-cancer therapy. The efficacy of various biomarker-oriented gene therapies was tested on both standard human cancer cell cultures and animal models.  \nHowever, let us have a candid discussion about how cancer biomarkers have been discovered, what their real values are for diagnostic and therapy, and how reliable their testing is on animal models and human cell cultures. Decades of work at almost all stages of both experimental and theoretical genomic research using numerous types of platforms entitle and oblige me to take the risky enterprise of discussing “the good, the bad and the ugly” of this paradigm. Studies of my lab-profiled cell cultures and tissues from surgically removed human tumors, as well as a wide variety of cells and tissues from animal (mouse, rat, rabbit, dog, chicken) models of human diseases. In addition to optimizing the wet protocols, we have introduced the Genomic Fabric Paradigm and developed advanced mathematical algorithms and computer software to analyze the genomic data.  \nThe GOOD (BMP promises) . Cancer is a multi-factorial disease regulated by an enormous number of widely diverse favoring conditioners, understanding of which is far from being compl","cbCaigMJxOlY62Tu","https://ap.wps.com/l/cbCaigMJxOlY62Tu","pdf",393792,"English","# Editorial overview\n## Molecular solutions and personalization goals\n## The biomarker paradigm: promise and rationale\n## Diagnostics and testing via biomarker panels\n## Economic incentives and standardization issues","[{\"question\":\"What is the main objective of the molecular solutions discussed in the editorial?\",\"answer\":\"To identify the most effective actionable molecules whose “smart” manipulation can selectively kill or slow cancer cell proliferation with few side effects on normal tissue cells.\"},{\"question\":\"Which types of evidence sources do the contributing authors use?\",\"answer\":\"They contribute through accurate experiments, reanalyzing publicly accessible genomic datasets such as TCGA, and writing comprehensive literature reviews.\"},{\"question\":\"Why does the editorial question the biomarker paradigm?\",\"answer\":\"It calls for a candid discussion about how biomarkers are discovered, their real value for diagnosis and therapy, and how reliable their testing is in animal models and human cell cultures.\"}]","Advanced Molecular Solutions for Cancer Therapy - The Good, the Bad, and the Ugly of the Biomarker Paradigm | PDF",1790027804,15]